Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals. The $100 million price tag is in the neighborhood of the going rate for these vouchers, which grant a company a shorter regulatory review timeline for a drug that addresses a rare or neglected disease.
Mallinckrodt Pharmaceuticals received FDA approval for its engineered skin product, StrataGraft, a treatment for serious thermal burns. The product is the latest to be reviewed under a new designation for regenerative medicines.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Citing unnamed sources, news outlets reported that Purdue would be dissolved to create a new company that would sell OxyContin and use proceeds to pay plaintiffs in more than 2,000 lawsuits filed by governments nationwide.
Joslin Diabetes Center CEO John Brooks III, has been forced out after four years with the business, two Mallinckrodt Pharmaceuticals subsidiaries are preparing to offer $750 million in unsecured notes to acquire TGG Medical Solutions